ArticleCancer2016

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.

Alexander Drilon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.